Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (81-90 of 383) with videos related to

Pageof 39
Sort By:
American Journal of Clinical Pathology|January 11, 2007
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevantZeba N Singh, Dezheng Huo, John Anastasi, et al.
American Journal of Hematology|May 23, 2022
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemiaCarlo Gambacorti-Passerini, Franck Emmanuel Nicolini, Richard A Larson, et al.
Investigational New Drugs|January 25, 2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemiaOlatoyosi M Odenike, Richard A Larson, Devika Gajria, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2004
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseasesOlatoyosi M Odenike, Ronald M Sobecks, Linda Janisch, et al.
Journal of Hematology & Oncology|November 30, 2012
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideEunice S Wang, Roger M Lyons, Richard A Larson, et al.
Cancer|January 2, 2009
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phaseHagop M Kantarjian, Richard A Larson, Francois Guilhot, et al.
Genes, Chromosomes & Cancer|January 21, 2004
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7Lucy E Side, Nicole P Curtiss, Kathryn Teel, et al.
British Journal of Haematology|June 17, 2014
The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q)Megan E McNerney, Christopher D Brown, April L Peterson, et al.
Blood Advances|April 14, 2022
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101Ellen K Ritchie, Heidi D Klepin, Elizabeth Storrick, et al.
Genes, Chromosomes & Cancer|April 30, 2002
t(1;3)(p36;p21) is a recurring therapy-related translocationYuko Sato, Tohru Izumi, Hirakazu Kanamori, et al.
Pageof 39

Showing results (81-90 of 383) with videos related to

Sort By:
Pageof 39
American Journal of Clinical Pathology|January 11, 2007
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevantZeba N Singh, Dezheng Huo, John Anastasi, et al.
American Journal of Hematology|May 23, 2022
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemiaCarlo Gambacorti-Passerini, Franck Emmanuel Nicolini, Richard A Larson, et al.
Investigational New Drugs|January 25, 2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemiaOlatoyosi M Odenike, Richard A Larson, Devika Gajria, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2004
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseasesOlatoyosi M Odenike, Ronald M Sobecks, Linda Janisch, et al.
Journal of Hematology & Oncology|November 30, 2012
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideEunice S Wang, Roger M Lyons, Richard A Larson, et al.
Cancer|January 2, 2009
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phaseHagop M Kantarjian, Richard A Larson, Francois Guilhot, et al.
Genes, Chromosomes & Cancer|January 21, 2004
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7Lucy E Side, Nicole P Curtiss, Kathryn Teel, et al.
British Journal of Haematology|June 17, 2014
The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q)Megan E McNerney, Christopher D Brown, April L Peterson, et al.
Blood Advances|April 14, 2022
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101Ellen K Ritchie, Heidi D Klepin, Elizabeth Storrick, et al.
Genes, Chromosomes & Cancer|April 30, 2002
t(1;3)(p36;p21) is a recurring therapy-related translocationYuko Sato, Tohru Izumi, Hirakazu Kanamori, et al.
Pageof 39